Neos Therapeutics (NEOS): Thoughts After Management Meetings - BMO

September 20, 2016 9:44 AM EDT
Get Alerts NEOS Hot Sheet
Price: $5.90 -0.84%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 35 | Down: 30 | New: 8
Trade NEOS Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

BMO Capital analyst, Gary Nachtman, reiterated his Outperform rating on shares of Neos Therapeutics (NASDAQ: NEOS) after meeting with management. The analyst remains positive on the Rx ramp for Adzenys XR-ODT, as well as the potential approvals/launches of Cotempla XRODT and NT-0201 in 2H17 that would improve operating leverage. Coverage for Adzenys XR-ODT has been progressing well, but gross-to-nets will continue to be a headwind for some time.

No change to the price target of $15.

For an analyst ratings summary and ratings history on Neos Therapeutics click here. For more ratings news on Neos Therapeutics click here.

Shares of Neos Therapeutics closed at $7.55 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

BMO Capital

Add Your Comment